A phase II trial of GW786034 (pazopanib) in patients with recurrent glioblastoma.

Trial Profile

A phase II trial of GW786034 (pazopanib) in patients with recurrent glioblastoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Mar 2017

At a glance

  • Drugs Pazopanib (Primary)
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions; Biomarker; Therapeutic Use
  • Most Recent Events

    • 25 Jan 2017 Trial focus has been changed from TU to TU and AR.
    • 04 May 2012 Actual end date changed from 1 Dec 2008 to 1 Mar 2009 as reported by ClinicalTrials.gov.
    • 12 Dec 2008 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top